In addition, 1 participant was excluded from the analysis of the AUC0-∞,t ½ and CL/F due to lack of data points for the calculation of t½. b A sensitivity analysis for Cmax provided a mean ER (90% CI) of 1.05 (0.88, 1.25) for the severe vs no hepatic impairment comparison. TABLE 4 Exploratory linear regressionstatistical analysis of the influence of the individual Child–Pugh parameters on the primary endpoint AUC0-∞ and Cmax Estimate of coefficient (95% CI) P AUC0-∞, nmol×h/L (N =4 2a) Albumin (serum) −0.012 ( −0.714, 0.690) .97 Total bilirubin (serum) 0.080 ( −0.085, 0.245) .33 Prothrombin time prolongation (plasma) + 1b −0.099 ( −0.270, 0.072) .25 Cmax, nmol/L (N =4 3a) Albumin (serum) −0.396 ( −1.302, 0.509) .38 Total bilirubin (serum) 0.077 ( −0.121, 0.274) .44 Prothrombin time prolongation (plasma) + 1b −0.087 ( −0.293, 0.118) .39 Abbreviations: AUC0-∞, area under the semaglutide concentration-time curve from time 0 to infinity; CI, confidence interval; Cmax, maximum semaglutide concentration; N, number of participants contributing to the analysis.